TABLE 4.
The impacts of monotherapy and combination therapy on the mortality of patients with CRE-BSI
| Antimicrobial regimen | No. of deceased patients/total no. of patients (%) | Logistic regression |
|||
|---|---|---|---|---|---|
| Univariate |
Multivariate |
||||
| OR (95% CI) | P value | Adjusted OR (95% CI)a | P value | ||
| With CAZ-AVI | |||||
| Monotherapy | 3/13 (23.1) | Reference | Reference | ||
| Combination therapy | 3/22 (13.6) | 0.526 (0.089–3.103) | 0.478 | 1.287 (0.124–13.403) | 0.833 |
| Without CAZ-AVI | |||||
| Monotherapy | 32/49 (65.3) | Reference | Reference | ||
| Combination therapy | 40/103 (38.8) | 0.337 (0.166–0.686) | 0.003 | 0.240 (0.077–0.745) | 0.014 |
a
Adjusted for Pitt score, meropenem MIC of ≥8 mg/liter, immunocompromised status, source control of infection, and appropriate empirical therapy.